Liquidia Corporation - Common Stock (LQDA)
15.06
-2.96 (-16.43%)
NASDAQ · Last Trade: Jun 10th, 1:54 PM EDT
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via Investor's Business Daily · June 10, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · June 10, 2025
Via Benzinga · June 10, 2025

Via Benzinga · June 2, 2025

Via Benzinga · May 30, 2025

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · May 30, 2025
Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics
Via Benzinga · May 27, 2025
The company’s proprietary dry-powder formulation, supported by Phase 3 data, is viewed as a promising alternative to United Therapeutics’ Tyvaso, though legal challenges remain pending.
Via Stocktwits · May 27, 2025
Via Benzinga · March 20, 2025

Via Benzinga · December 26, 2024